Thursday, November 19, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 57
Confirmed by 2 outlets

FDA clears Regeneron's RNAi myasthenia drug at $410,000 a year

Regeneron won FDA approval Wednesday for Livsayis, the first RNA interference drug cleared for an autoimmune disease, targeting generalized myasthenia gravis. The four-times-a-year shot lists at $410,000 for a year's supply. It's discovered by Alnylam and now faces Argenx and AstraZeneca in a crowded market.

By the Paparazzi desk November 19, 2026 · 7:10 AM · Sources: 2 outlets · 0 views
Fact boxTrust 58/100 · Developing
What we verified
  • 2 sources report it: finance.yahoo.com, biopharmadive.com.
  • The source published it on Nov 19, 2026 at 7:10 AM.
What we couldn't

Nothing open. Every check passed.

Regeneron Pharmaceuticals picked up FDA approval Wednesday for Livsayis, a first-of-its-kind RNA interference therapy for generalized myasthenia gravis. The drug works by blocking production of C5, a protein tangled up in the errant immune attack behind the disease. It's cleared for adults with the most common form, the AChR antibody-positive kind.

The price tag is steep: a year's supply lists at $410,000, according to a Regeneron spokesperson. Regeneron is pitching convenience as the sell — Livsayis goes in as a subcutaneous injection four times a year. By contrast, AstraZeneca's newly approved Klygefa is dosed once a week.

Sponsored

Alnylam Pharmaceuticals discovered the drug and handed it to Regeneron in 2019 under a broad RNAi partnership. It arrived via a detour: Alnylam first aimed the compound, then called cemdisiran, at paroxysmal nocturnal hemoglobinuria, but it fell short as a monotherapy in early testing. That pushed a strategic pivot toward combination approaches and other inflammatory targets, myasthenia gravis among them.

Livsayis lands in a crowded room. It competes with a popular Argenx medicine and several AstraZeneca drugs that hit C5 in different ways. RBC Capital Markets analyst Brian Abrahams wrote that uptake is likely to be, quote, measured at first.

The approval matters beyond myasthenia gravis. Eight RNAi medicines had reached market before this one, most of them sold by Alnylam and aimed at rare diseases. Livsayis is the first RNAi drug approved for an autoimmune condition, a sign the technology is maturing alongside small molecules and antibodies.

For Regeneron, it's a chance to branch into immunology while it absorbs growing biosimilar competition for its flagship eye drug Eylea and braces for the eventual patent loss on anti-inflammatory blockbuster Dupixent. The company is also awaiting readouts on a new kind of blood thinner and an RNAi therapy for a common liver disease.

TopicsRegeneron Pharmaceuticals · Alnylam Pharmaceuticals · FDA · Livsayis · Argenx · AstraZeneca · Eylea · Dupixent

Share

Written by AI from verified reporting.

More stories

  • Health & science 16:16 UTC · 35 minutes ago · apnews.com · 0 views
    A spacecraft's call takes 24 hours to cross 16 billion miles to Earth
  • Health & science 15:46 UTC · 1 hour ago · theguardian.com · 1 view
    New Report Reveals Over 500 Moves To Roll Back Cancer Protections
  • Health & science 14:02 UTC · 3 hours ago · finance.yahoo.com 3 sources· 1 view
    Humacyte Files FDA Application to Add Dialysis Access as Second ATEV Use
  • Health & science 13:01 UTC · 4 hours ago · technologyreview.com · 1 view
    Donated liver survives seven weeks outside the body in Sydney record
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.